TOKYO - Japanese pharmaceutical firm Shionogi & Co. said Friday it has applied for approval of its oral COVID-19 drug, after mid-phase clinical trials showed efficacy in reducing the coronavirus in the body.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
